Joseph Schwartz
Stock Analyst at Leerink Partners
(1.70)
# 3,092
Out of 4,711 analysts
142
Total ratings
32.52%
Success rate
-2.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $17.18 | +132.83% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.88 | +1,490.73% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $4.35 | -8.05% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.26 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $4.16 | +188.46% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $3.35 | +138.81% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.59 | +277.36% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.40 | +400.00% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.42 | -29.58% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $6.25 | -4.00% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $46.24 | +3.81% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $19.57 | -8.02% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $8.36 | +139.23% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $35.63 | -4.57% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $65.66 | +97.99% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $118.97 | +34.49% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $136.38 | +19.52% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $0.84 | +1,090.48% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $3.63 | +809.09% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $9.03 | +32.89% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $44.22 | +144.23% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $70.44 | -29.02% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $53.60 | -27.24% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $2.24 | +78.57% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $30.78 | -2.53% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $31.82 | +57.13% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $41.49 | -27.69% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $16.98 | +229.80% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.80 | +42.86% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.63 | +356.27% | 2 | Sep 26, 2017 |
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $17.18
Upside: +132.83%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.88
Upside: +1,490.73%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $4.35
Upside: -8.05%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.26
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $4.16
Upside: +188.46%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $3.35
Upside: +138.81%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.59
Upside: +277.36%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.40
Upside: +400.00%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.42
Upside: -29.58%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $6.25
Upside: -4.00%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $46.24
Upside: +3.81%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $19.57
Upside: -8.02%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $8.36
Upside: +139.23%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $35.63
Upside: -4.57%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $65.66
Upside: +97.99%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $118.97
Upside: +34.49%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $136.38
Upside: +19.52%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.84
Upside: +1,090.48%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $3.63
Upside: +809.09%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $9.03
Upside: +32.89%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $44.22
Upside: +144.23%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $70.44
Upside: -29.02%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $53.60
Upside: -27.24%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $2.24
Upside: +78.57%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $30.78
Upside: -2.53%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $31.82
Upside: +57.13%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $41.49
Upside: -27.69%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $16.98
Upside: +229.80%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.80
Upside: +42.86%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.63
Upside: +356.27%